医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

 ABE Technology Introduces AI-Enhanced Cardiac Imaging System ‘CardioVision’

2024年06月12日 AM11:03
このエントリーをはてなブックマークに追加


 

HONG KONG

ABE Technology has announced the launch of its latest innovation, CardioVision, an AI-powered cardiac imaging system designed to improve the efficiency and accuracy of cardiac diagnostics. This new system integrates advanced artificial intelligence to streamline imaging processes and enhance patient care.

CardioVision: Enhancing Cardiac Diagnostics
CardioVision utilizes advanced AI algorithms to refine imaging quality and diagnostic accuracy. Key features include:

  • AI-Driven Diagnostics: These algorithms provide precise and reliable imaging results, essential for addressing complex cardiac conditions.
  • Workflow Efficiency: Automated features like patient isocentering and advanced image reconstruction reduce the duration of imaging procedures, enabling quicker, more efficient workflows.
  • Focus on Patient Care: By automating routine imaging tasks, CardioVision allows medical staff to focus more on direct patient care.

Leadership Commentary
“Our development of CardioVision was in direct response to the needs expressed by cardiologists and radiologists,” stated Dr. Lee Chan, Chief Technology Officer at ABE Technology. “This system is designed to make cardiac diagnostics more accurate and less time-consuming.”

Clinical Testing and Future Outlook
Preliminary testing of CardioVision in several medical facilities has demonstrated excellent results, enhancing both the quality of imaging and the efficiency of the diagnostic process. ABE Technology plans to extend these trials to further validate the system’s effectiveness across different environments.

About ABE Technology
Established in 2017 in Hong Kong, ABE Technology specializes in integrating AI and machine learning into cardiac imaging. The company aims to improve the precision, efficiency, and accessibility of cardiac diagnostics, contributing to better patient outcomes worldwide.

Ongoing Research and Development
ABE Technology is committed to expanding its research into new AI applications for cardiac care, including predictive analytics and personalized treatment plans. These efforts aim to continually improve the functionality and impact of its diagnostic tools in real-world settings.

Engagement and Industry Interest
The introduction of CardioVision has already attracted interest from several healthcare organizations, which see potential in enhancing their cardiac care services through this advanced imaging technology. Discussions about potential collaborations are ongoing, highlighting the industry’s interest in AI-driven innovations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240611476953/en/

CONTACT

Media Contact:

Kin Huang

Investor Relations Manager

ABE Technology (H.K.) Company Limited

Web: https://abethealth.com

Email: ir@abethealth.com

Phone: +852 5819 6989

同じカテゴリーの記事 

  • Celltrion公布皮下注射英夫利西单抗(CT-P13 SC)的两年事后分析结果,强调剂量递增是控制炎症性肠病继发性失应答的可选方案
  • メディデータ、初期および後期臨床試験をサポートするRave Liteを発表
  • Medidata宣布推出Rave Lite以支持早期和后期临床试验的增长
  • サウジアラビア開発基金、セルビアとの初の提携で 3件の開発プロジェクトに2億500万ドルの拠出を発表
  • 沙特发展基金宣布首次进入塞尔维亚 ,资助三个发展项目,总额达2.05亿美元